RxDoctor Payments Data

Stacey Ritz, OD

Optometrist · Latham, NYNPI 1649230624

Payments from drug & device makers

$3,313in general payments, 2019–2025

Across 174 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$574
  • Bausch & Lomb Americas Inc.$493
  • AbbVie$447
  • Oyster Point Pharma, Inc.$348
  • Sun Pharmaceutical Industries Inc.$276
  • Dompe US, Inc.$246
  • plus $928 from 9 others

What the payments were for

  • Food & beverage$3,310100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,313 in reported general payments places this provider in the 85th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$73,687
Medicare patients
338
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine69$98,851
LumiganBimatoprost79$51,628
XiidraLifitegrast20$37,264
Cyclosporine36$13,138
VyzultaLatanoprostene Bunod34$12,831
MieboPerfluorohexyloctane/Pf16$12,046
RhopressaNetarsudil Mesylate14$7,534
Travoprost13$1,697
Latanoprost103$1,360
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha61$961
ErythromycinErythromycin Base34$686
Tobramycin-DexamethasoneTobramycin/Dexamethasone13$632
Timolol Maleate34$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$447$150,478148 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$493$62,14170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,743 optometrist providers in New York.

Other optometrist in Latham

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →